Patents by Inventor Taylor SANDISON

Taylor SANDISON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240108684
    Abstract: The disclosure features pharmaceutical compositions, methods, and kits featuring dosing regimens and CD101, or a pharmaceutical acceptable salt or neutral form thereof (e.g., CD101 acetate).
    Type: Application
    Filed: June 5, 2023
    Publication date: April 4, 2024
    Inventors: Kenneth BARTIZAL, Paul DARUWALA, Jeffrey Brian LOCKE, Voon ONG, Taylor SANDISON, Dirk THYE
  • Publication number: 20240076347
    Abstract: Provided herein are methods for preventing or reducing the likelihood of a fungal infection or related conditions thereto in a human subject in need thereof. The methods include the administration of one or multiple doses of a pharmaceutical composition including CD101 and any pharmaceutically acceptable excipients, wherein the treatment reduces or eliminates the likelihood of developing a fungal infection.
    Type: Application
    Filed: January 27, 2023
    Publication date: March 7, 2024
    Inventors: Kenneth BARTIZAL, Paul Daruwala, Kevin Forrest, Brendan Hannah, Voon Ong, Maureen Roden, Taylor Sandison
  • Publication number: 20230405082
    Abstract: Provided herein are methods of identifying an individual having or at risk of developing intra-abdominal candidiasis (IAC) and treating, mitigating, or preventing IAC in the individual by administering a pharmaceutical composition including CD101, in salt or neutral form, in an amount sufficient to effectively treat or prevent IAC.
    Type: Application
    Filed: January 20, 2023
    Publication date: December 21, 2023
    Inventors: Kenneth BARTIZAL, Paul Daruwala, Voon Ong, Taylor Sandison
  • Patent number: 11712459
    Abstract: The disclosure features pharmaceutical compositions, methods, and kits featuring dosing regimens and CD101, or a pharmaceutical acceptable salt or neutral form thereof (e.g., CD101 acetate).
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: August 1, 2023
    Assignee: Cidara Therapeutics, Inc.
    Inventors: Kenneth Bartizal, Paul Daruwala, Jeffrey Brian Locke, Voon Ong, Taylor Sandison, Dirk Thye
  • Publication number: 20230181689
    Abstract: Provided herein are methods for treating, mitigating, or preventing fungal infections or related conditions thereto in a human subject in need thereof. The methods include the administration of a single dose of a pharmaceutical composition comprising or consisting of CD101 and any pharmaceutically acceptable excipients, wherein the single dose treatment substantially reduces or eliminates the fungal infection.
    Type: Application
    Filed: August 4, 2022
    Publication date: June 15, 2023
    Inventors: Kenneth BARTIZAL, Paul DARUWALA, Jeffrey B. LOCKE, Voon ONG, Taylor SANDISON
  • Publication number: 20210002346
    Abstract: Provided herein are methods for preventing or reducing the likelihood of a fungal infection or related conditions thereto in a human subject in need thereof. The methods include the administration of one or multiple doses of a pharmaceutical composition including CD1 01 and any pharmaceutically acceptable excipients, wherein the treatment reduces or eliminates the likelihood of developing a fungal infection.
    Type: Application
    Filed: November 29, 2017
    Publication date: January 7, 2021
    Inventors: Kenneth BARTIZAL, Paul DARUWALA, Kevin FORREST, Brendan HANNAH, Voon ONG, Maureen RODEN, Taylor SANDISON
  • Patent number: 10780144
    Abstract: The disclosure relates to methods of prophylactic and therapeutic treatments of a Pneumocystis infection (i.e., an infection caused by Pneumocystis jirovecii) in a subject by administering to the subject a compound of any of formulas (I)-(III) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of a Pneumocystis spp. The methods of the disclosure can be useful in immunocompromised subjects.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: September 22, 2020
    Assignee: Cidara Therapeutics, Inc.
    Inventors: Kenneth Bartizal, Paul Daruwala, Voon Ong, Maureen Roden, Taylor Sandison, Dirk Thye
  • Publication number: 20200164023
    Abstract: Provided herein are methods of identifying an individual having or at risk of developing intra-abdominal candidiasis (1AC) and treating, mitigating, or preventing 1AC in the individual by administering a pharmaceutical composition including CD1 01, in salt or neutral form, in an amount sufficient to effectively treat or prevent 1AC.
    Type: Application
    Filed: January 23, 2018
    Publication date: May 28, 2020
    Inventors: Kenneth BARTIZAL, Paul DARUWALA, Voon ONG, Taylor SANDISON
  • Publication number: 20200164022
    Abstract: The disclosure relates to methods of prophylactic and therapeutic treatments of a Pneumocystis infection (i.e., an infection caused by Pneumocystis jirovecii) in a subject by administering to the subject a compound of any of formulas (I)-(III) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of a Pneumocystis spp. The methods of the disclosure can be useful in immunocompromised subjects.
    Type: Application
    Filed: August 1, 2019
    Publication date: May 28, 2020
    Inventors: Kenneth BARTIZAL, Paul DARUWALA, Voon ONG, Maureen RODEN, Taylor SANDISON, Dirk THYE
  • Publication number: 20190307843
    Abstract: Provided herein are methods for treating, mitigating, or preventing fungal infections or related conditions thereto in a human subject in need thereof. The methods include the administration of a single dose of a pharmaceutical composition comprising or consisting of CD101 and any pharmaceutically acceptable excipients, wherein the single dose treatment substantially reduces or eliminates the fungal infection.
    Type: Application
    Filed: October 30, 2017
    Publication date: October 10, 2019
    Inventors: Kenneth BARTIZAL, Paul DARUWALA, Jeffrey B. LOCKE, Voon ONG, Taylor SANDISON
  • Patent number: 10369188
    Abstract: The disclosure relates to methods of prophylactic and therapeutic treatments of a Pneumocystis infection (i.e., an infection caused by Pneumocystis jirovecii) in a subject by administering to the subject a compound of any of formulas (1)-(111) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of a Pneumocystis spp. The methods of the disclosure can be useful in immunocompromized subjects.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: August 6, 2019
    Assignee: Cidara Therapeutics, Inc.
    Inventors: Kenneth Bartizal, Paul Daruwala, Voon Ong, Maureen Roden, Taylor Sandison, Dirk Thye
  • Publication number: 20190216885
    Abstract: The disclosure features pharmaceutical compositions, methods, and kits featuring dosing regimens and CD101, or a pharmaceutical acceptable salt or neutral form thereof (e.g., CD101 acetate).
    Type: Application
    Filed: March 15, 2017
    Publication date: July 18, 2019
    Inventors: Kenneth BARTIZAL, Paul DARUWALA, Jeffrey Brian LOCKE, Voon ONG, Taylor SANDISON, Dirk THYE
  • Publication number: 20190000917
    Abstract: The disclosure relates to methods of prophylactic and therapeutic treatments of a Pneumocystis infection (i.e., an infection caused by Pneumocystis jirovecii) in a subject by administering to the subject a compound of any of formulas (1)-(111) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of a Pneumocystis spp. The methods of the disclosure can be useful in immunocompromised subjects.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 3, 2019
    Inventors: Kenneth BARTIZAL, Paul DARUWALA, Voon ONG, Maureen RODEN, Taylor SANDISON, Dirk THYE
  • Publication number: 20180256673
    Abstract: The disclosure relates to methods of treating a fungal infection in a subject by administering to the subject a salt of Compound 1, or a neutral form thereof. The methods of the disclosure can be useful in subjects suffering from treatment resistant infections, useful in subjects who have previously failed treatment with an anti-fungal therapy, and useful for suppressing the emergence of resistant strains in infected subjects.
    Type: Application
    Filed: September 16, 2016
    Publication date: September 13, 2018
    Inventors: James Michael BALKOVEC, Kenneth BARTIZAL, Jeffrey Brian LOCKE, Voon ONG, Taylor SANDISON, Dirk THYE, David S. PERLIN, Kenneth Duke JAMES, Jr.